Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL212320 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL182591 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL9838279 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL5930978 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL182590 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL17627562 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL28706585 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1462474 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL7369132 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL4818293 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7537888-B2 | Marker assisted selection of bovine for improved milk production using diacylglycerol acyltransferase gene DGAT1 | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2009-05-26 | — | — | US | claimed |
| US-7407750-B2 | Marker assisted selection of bovine for improved milk composition | BLOTT SARAH | 2008-08-05 | — | — | US | claimed |
| US-7355029-B2 | Genes encoding carbon metabolism and energy-producing proteins | BASF AG (DE) | 2008-04-08 | — | — | US | claimed |
| EP-1330552-B1 | MARKER ASSISTED SELECTION OF BOVINE FOR IMPROVED MILK PRODUCTION USING DIACYLGLYCEROL ACYLTRANSFERASE GENE DGAT1 | GEORGES MICHEL ALPHONSE JULIEN (BE) | 2007-01-24 | — | — | EP | claimed |
| US-5466781-A | Isolation of bodies, suspension, agitation and centrifuging | CHIRON THERAPEUTICS (US) | 1995-11-14 | — | — | US | claimed |
| US-4816131-A | SEMIPERMEABLE LIQUID MEMBRANE | THE BOARD OF REGENTS OF THE UNIVERSITY OF WASHINGTON (US) | 1989-03-28 | — | — | US | claimed |
| US-12029780-B2 | Long-acting polypeptides and methods of producing and administering same | OPKO BIOLOGICS LTD. (IL) | 2024-07-09 | — | — | US | disclosed |
| US-20240197907-A1 | Dual-Cleavage Ester Linkers for Antibody-Drug Conjugates | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2024-06-20 | — | — | US | disclosed |
| US-20240139105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GHRP-6 | CT INGENIERIA GENETICA BIOTECNOLOGIA (CU) | 2024-05-02 | — | — | US | disclosed |
| WO-2024042318-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) TO A TCR BETA-CHAIN VARIABLE REGION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2024-02-29 | — | — | WO | disclosed |
| EP-3482765-B1 | LONG-ACTING GROWTH HORMONE AND METHODS OF PRODUCING SAME | OPKO BIOLOGICS LTD (IL) | 2024-02-28 | — | — | EP | disclosed |
| EP-4285891-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GHRP-6 | Centro de Ingeniería Genética y Biotecnología (CU) | 2023-12-06 | — | — | EP | disclosed |
| EP-4277662-A1 | DUAL-CLEAVAGE ESTER LINKERS FOR ANTIBODY-DRUG CONJUGATES | R.P. Scherer Technologies, LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-5589572-A | Process for production of inhibited forms of activated blood factors | COR THERAPEUTICS, INC. (US) | 1996-12-31 | — | — | US | disclosed |
| US-5589571-A | Process for production of inhibited forms of activated blood factors | COR THERAPEUTICS, INC. (US) | 1996-12-31 | — | — | US | disclosed |
| US-5247950-A | Control of static burning rate by use of binary burnign chemical combinations | P. H. GLATFELTER COMPANY (US) | 1993-09-28 | — | — | US | disclosed |
| US-5219555-A | Coupling isotopes with macrocyclic amines; diagnosis | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-06-15 | — | — | US | disclosed |
| WO-1991004672-A1 | TREATMENT OF ANIMAL BLOOD | KALINOWSKI ANDREW (AU) | 1991-04-18 | — | — | WO | disclosed |
| US-4968675-A | SIDE EFFECT REDUCTION OF TRIENE STEROID | UPJOHN (US) | 1990-11-06 | — | — | US | disclosed |
| US-4544491-A | Recovery of hydrocarbon oil from filter cakes | CLAYPRO ASSOCIATES (US) | 1985-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197907-A1 | Dual-Cleavage Ester Linkers for Antibody-Drug Conjugates | ADAM8, BCR, JMJD7 | MEN1 2741/4885ALDH1A1 875/4885HMGCR 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.